41 related articles for article (PubMed ID: 10584682)
21. Parkinson's disease: recent advances in therapy.
Jankovic J
South Med J; 1988 Aug; 81(8):1021-7. PubMed ID: 3043683
[No Abstract] [Full Text] [Related]
22. Medical treatment of Parkinson's disease.
Ahlskog JE
Compr Ther; 1989 Mar; 15(3):53-9. PubMed ID: 2650977
[No Abstract] [Full Text] [Related]
23. [Role and regulation of dopamine D1 receptors in the striatum: implications for the genesis of dyskinesia in Parkinson's disease].
Corvol JC; Girault JA; Hervé D
Rev Neurol (Paris); 2006 Jun; 162(6-7):691-702. PubMed ID: 16840977
[TBL] [Abstract][Full Text] [Related]
24. What has PET told us about Parkinson's disease?
Aquilonius SM
Acta Neurol Scand Suppl; 1991; 136():37-9. PubMed ID: 1801535
[TBL] [Abstract][Full Text] [Related]
25. The use of PET in Parkinson's disease.
Shinotoh H; Calne DB
Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
[TBL] [Abstract][Full Text] [Related]
26. [Clinical studies with levodopa/carbidopa intestinal gel].
Klivényi P; Vécsei L
Ideggyogy Sz; 2014 Jan; 67(1-2):5-8. PubMed ID: 24654442
[TBL] [Abstract][Full Text] [Related]
27. Pathophysiology of movement disorders studied using PET.
Leenders KL
J Neural Transm Suppl; 1997; 50():39-46. PubMed ID: 9120423
[TBL] [Abstract][Full Text] [Related]
28. Advances in imaging Parkinson's disease.
Brooks DJ
Curr Opin Neurol; 1997 Aug; 10(4):327-31. PubMed ID: 9266157
[TBL] [Abstract][Full Text] [Related]
29. Optimisation of [11C]Raclopride production using a Synthra GPextent system.
Perkins G; Sheth R; Greguric I; Pascali G
Curr Radiopharm; 2014; 7(2):100-6. PubMed ID: 25335809
[TBL] [Abstract][Full Text] [Related]
30. [Advantages and limitations in the assessment of neuroprotective treatment of Parkinson's disease by functional imaging].
Thobois S; Broussolle E; Remy P
Rev Neurol (Paris); 2005 Apr; 161(4):385-93. PubMed ID: 15924074
[TBL] [Abstract][Full Text] [Related]
31. Role of [18F]-dopa-PET imaging in assessing movement disorders.
Fischman AJ
Radiol Clin North Am; 2005 Jan; 43(1):93-106. PubMed ID: 15693650
[TBL] [Abstract][Full Text] [Related]
32. Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia.
Calne DB; de la Fuente-Fernández R; Kishore A
J Neural Transm Suppl; 1997; 50():47-52. PubMed ID: 9120424
[TBL] [Abstract][Full Text] [Related]
33. Parkinson's disease: imaging update.
de la Fuente-Fernández R; Stoessl AJ
Curr Opin Neurol; 2002 Aug; 15(4):477-82. PubMed ID: 12151846
[TBL] [Abstract][Full Text] [Related]
34. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
Dentresangle C; Veyre L; Le Bars D; Pierre C; Lavenne F; Pollak P; Guerin J; Froment JC; Brousolle E
Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
[No Abstract] [Full Text] [Related]
35. PET studies and motor complications in Parkinson's disease.
Brooks DJ
Trends Neurosci; 2000 Oct; 23(10 Suppl):S101-8. PubMed ID: 11052227
[TBL] [Abstract][Full Text] [Related]
36. Duopa--a carbidopa/levodopa enteral suspension for Parkinson's disease.
Med Lett Drugs Ther; 2015 Aug; 57(1474):112. PubMed ID: 26218794
[No Abstract] [Full Text] [Related]
37. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo).
Silver DE
Expert Rev Neurother; 2004 Jul; 4(4):589-99. PubMed ID: 15853578
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
